Resources

Our latest news, blogs, reports, publications and upcoming events






























News, blogs, events, reports and more

Read our latest press releases, hear our most recent media appearances, and see which upcoming events we are attending.

Subscribe to our social channels to ensure you get our updates, news and announcements as and when they happen.




Share
LinkedIn X Link



Blogs
07 August 2026
How to study the endosomal escape of RNA therapeutics

How to study the endosomal escape of RNA therapeutics





Events
08 September 2026
Nordic Life Science Days 2026 – Stockholm

MDC are attending Nordic Life Science Days in Stockholm, Sweden, from the 8-9 September 2026


Events
17 October 2026
EANM 2026 – Vienna

MDC and NPIP are exhibiting at EANM 2026 in Vienna, Austria. 


Events
14 October 2026
ELRIG 2026 – London

MDC are exhibiting at ELRIG Drug Discovery 2026, at Excel, London. 


SMR
Events
04 September 2026
SMR Radiopharmaceuticals – Cambridge

Come and visit MDC at our booth at the event – more information to follow.


Blogs
27 July 2026
Xenium at MDC Case Study: Hypoxia in Head and Neck Cancer

Xenium at MDC Case Study: Hypoxia in Head and Neck Cancer


News
22 July 2026
UK Intracellular Drug Delivery Centre opens for industry access to accelerate next-generation RNA medicines 

The centre will provide integrated expertise and evidence generation to help innovators accelerate the development of next-generation RNA medicines.


Blogs
15 July 2026
Live-cell imaging – Fixation Vs Reality

From mitochondrial networks that silently rebalance fusion and fission, to chromosomes that only reveal their fate in the minutes after division, live-cell imaging uncovers dynamics that static snapshots miss entirely. We explore three examples, including how tracking RNA therapeutic vehicles as they transit and escape endosomal compartments in real time resolves ambiguity that even super-resolution imaging of fixed cells can’t overcome.


Blogs
05 July 2026
From Photons to Phenotype

By looking beyond the diffraction limit, we have established a method to quantitatively distinguish low-grade breast cancers that appear identical by traditional means. Ultimately, this nanoscale insight could expand access to novel HER2-targeted therapies by reliably identifying low expressing cohorts that would benefit from intervention.






Partner with us and make sure your next move counts

See how we can help support you with your next drug discovery project.

Speak to us



Medicines Discovery Catapult